BMJ · 1971 · 29 citations · 19 references
MedicineCardiologyPharmacologyCardiovascular PharmacotherapyClinical PharmacologyPharmacodynamicsAntiarrhythmic TherapyArrhythmia PharmacotherapyCardiac MedicationsCardiac PharmacotherapyCardiovascular Drug SafetyCardiovascular PharmacologyAntiarrhythmic Drug EffectsAntiarrhythmic MedicationsAntiarrhythmic PharmacologyManagement Of Ventricular TachycardiaMyocardial Infarction PharmacotherapyPharmacodynamics Of Antiarrhythmic DrugsSupraventricular Tachycardia PharmacotherapySympathomimetic Pharmacology
Oxprenolol, a new beta-receptor blocking drug with intrinsic sympathomimetic activity, was used to treat 63 episodes of cardiac arrhythmia occurring in 43 patients with acute myocardial infarction or myocardial ischaemia. The drug was most effective in abolishing ventricular ectopic beats and supraventricular tachycardia. The best method of administration was by continuous intravenous infusion and the most satisfactory bolus does was 6 mg. The main side effect was hypotension, which occurred in 59% of episodes of arrhythmia that had responded previously to intravenous administration. Oxprenolol was often effective in lignocaine-resistant arrhythmia. The two main advantages of oxprenolol over propranolol are the reduced likelihood of adversely affecting myocardial function and the diminished tendency to produce bronchospasm.
19
A JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Journal of the American Medical Association · 1909 · 7.9K citations · Full text
EFFECT OF A β-ADRENERGIC-BLOCKING AGENT, PROPRANOLOL, ON ASTHMATICS
R. S. McNeill · The Lancet · 1964 · 309 citations
Unwanted effects of propranolol
Stewart A. Stephen · The American Journal of Cardiology · 1966 · 297 citations
Beta-adrenergic Receptor Blockade in Cardiac Arrhythmias
J. P. P. Stock, Nicole Dale · BMJ · 1963 · 169 citations · Full text